Comparison of the efficacy and adverse effects of sustained-release buprenorphine hydrochloride following subcutaneous administration and buprenorphine hydrochloride following oral transmucosal administration in cats undergoing ovariohysterectomy

Catbagan, Davina L.; Quimby, Jessica M.; Mama, Khursheed R.; Rychel, Jessica K.; Mich, Patrice M.

doi:10.2460/ajvr.72.4.461

Cited by 62 publications

(42 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study has suggested an analgesic effect of ER-Bup, however the pain evaluations consisted of two non-validated subjective pain scales [23] and no placebo group. In contrast, our study showed a clear analgesic effect over a 72 h period postoperatively using objective measures and a control group comparison.…”

Section: Discussionmentioning

confidence: 99%

“…Evaluation of an extended release formulation of buprenorphine in dogs undergoing arthrotomy provided pain relief over a 72 h period [22]. In cats, it has been reported that the administration of a single dose of ER-Bup had a similar efficacy (as evaluated by subjective pain assessment scales) and adverse effect profile as twice-daily oral transmucosal administration of buprenorphine [23]. However, there was no placebo control group in this study, and the investigators did not use a validated subjective assessment tool, and so the efficacy of the new formulation of buprenorphine is unknown.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pilot evaluation of a novel unilateral onychectomy model and efficacy of an extended release buprenorphine product

et al. 2016

View full text Add to dashboard Cite

BackgroundNon-steroidal anti-inflammatory drugs (NSAIDs), transdermal fentanyl patches, and transmucosal buprenorphine are probably the most commonly used options for providing post-operative analgesia in the early at-home period. However, these require daily administration or are associated with abuse concerns. One of the significant unmet needs in veterinary surgery and pain management is for longer acting opioids for cats to effectively bridge the gap between the in-hospital and at-home recovery periods.A proof of concept study of an extended release formulation of buprenorphine HCL (ER-Bup) was conducted using objective kinetic measures and a unilateral onychectomy model. Using a blinded, randomized, two period crossover design, four cats were allocated to control (saline) or ER-Bup (0.6 mg/kg, subcutaneously [SC]) treatment groups. All animals underwent a unilateral forelimb onychectomy per period with a washout/recovery period in between. Observational pain scores and kinetic data (using a pressure sensitive walkway [PSW]) were collected prior to (baseline) and at intervals for 72 h following surgery. Symmetry indices were derived for kinetic variables (peak vertical force [PVF]; vertical impulse [VI]) of each forelimb for landing following a jump and for walking. A rescue analgesic protocol was in place. Effect of surgery and treatment were evaluated using a mixed model statistical approach.ResultsNo cats required rescue analgesics based on subjective pain score. ER-Bup had a positive influence on subjective pain scores during the 72 h postsurgery (p = 0.0473). PVF and VI of the operated limb were significantly decreased for both landing (p < 0.0001 and p < 0.0001) and walking (p < 0.0001 and p < 0.0001 respectively) compared to control. ER-Bup resulted in significantly decreased asymmetry in limb use during landing (PVF, p < 0.0001; VI, p < 0.0001) and walking (PVF, p = 0.0002, VI, p < 0.0001). The novel use of data collected following a jump from an elevated platform appeared to provide all desired information and was easier to collect than walking data.ConclusionThis study demonstrates that SC administration of ER-Bup may be an effective analgesic for a 72 h period postoperatively. Furthermore, landing onto a PSW from an elevated perch may be a useful and efficient way to assess analgesics in cats using a unilateral model of limb pain.Electronic supplementary materialThe online version of this article (doi:10.1186/s12917-017-0943-5) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Pilot evaluation of a novel unilateral onychectomy model and efficacy of an extended release buprenorphine product

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The latter formulation should not be confused with the new FDA‐indexed extended release buprenorphine HCl (1.3 mg/mL; Animalgesics ® ; Animalgesic Labs, Millersville, MD, USA) for mice and rats. There is currently a lack of studies on buprenorphine SR PK and PD effects in dogs and cats (Catbagan et al ., ; Nunamaker et al ., ). One study has reported that dogs undergoing ovariohysterectomy maintained adequate levels of analgesia with this sustained‐release formulation in combination with meloxicam for approximately 136 ± 11 h with minimal adverse effects (Nunamaker et al ., ).…”

Section: Current Knowledge Misconceptions and Controversies: The Romentioning

confidence: 96%

“…As discussed later in this review, the analgesic effects of buprenorphine after OTM administration for feline ovariohysterectomy is questionable and this information does necessarily mean that buprenorphine SR produces adequate pain relief. In addition, meloxicam was administered to all cats in that study adding an important confounding factor (Catbagan et al ., ). Simbadol ® (Zoetis) or SR formulations should not be confused with other brands (Vetergesic ® , Temgesic ® , Buprenex ® ) using lower concentrations (0.3 mg/mL) of buprenorphine.…”

Section: Current Knowledge Misconceptions and Controversies: The Romentioning

confidence: 97%

The present and future of opioid analgesics in small animal practice

Simon

Steagall

2016

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Opioids are the cornerstone for the treatment of acute pain in small animal patients. This is primarily because of their remarkable safety profile, high efficacy, and benefit of reversibility. There have been some significant advances in our knowledge on opioid pharmacology and clinical usage in companion animal medicine. This review discusses the progression of opioid use in small animal practice providing current misconceptions and controversies in light of routes of administration. Potential targets for research and drug development and novel therapies are discussed in addition to the concepts of glial cell modulators, individual variability, and opioid tolerance and hyperalgesia. The future brings an interesting perspective with the application of pharmacogenetics and individualized pain management in canine and feline practice.

show abstract

“…Anecdotally, a long-sustained release formulation of buprenorphine has been advocated to provide analgesia for up to 5 days in cats. 22 However, at the time of writing, there were no reports of the long-acting analgesic effects of this compound in veterinary medicine. The administration of NSAID has been recommended at a progressively decreasing dosing schedule for up to 12 days.…”

Section: Treatment Of Chronic Pain Syndromementioning

confidence: 99%

Skin and Musculoskeletal Diseases

Steagall

2014

Canine and Feline Anesthesia and Co‐Existing Disease

View full text Add to dashboard Cite

Comparison of the efficacy and adverse effects of sustained-release buprenorphine hydrochloride following subcutaneous administration and buprenorphine hydrochloride following oral transmucosal administration in cats undergoing ovariohysterectomy

Abstract: In cats undergoing ovariohysterectomy, SC administration of a preoperative dose of SR buprenorphine appeared to have comparable efficacy and adverse effect profile as that of twice-daily OTM administration of buprenorphine before and after surgery.

Cited by 62 publications

References 11 publications

Pilot evaluation of a novel unilateral onychectomy model and efficacy of an extended release buprenorphine product

Pilot evaluation of a novel unilateral onychectomy model and efficacy of an extended release buprenorphine product

The present and future of opioid analgesics in small animal practice

Skin and Musculoskeletal Diseases

Contact Info

Product

Resources

About